Pergoveris (follitropin alfa;lutropin alfa)
- Region
- 🇪🇺 EU
- Active substance
- follitropin alfa;lutropin alfa
- Company
- Merck Europe B.V.
- Status
- Authorised
- Therapeutic area
- Infertility, Female
- EU approval
- Mon 25 Jun 2007
- Application
- EMEA/H/C/000714
- ATC
- G03GA30
- Official record
- www.ema.europa.eu
Indication
Pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (LH) and follicle-stimulating-hormone deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/l.
Regulatory milestones
No milestones recorded in the last year.
Follow Pergoveris
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.